top of page

Clinical Trials

Epygenix Candidates in Clinical Trials

Our pipeline of candidates includes multiple innovative drugs at varying stages of development. Our lead investigational drug, EPX-100, is currently in a pivotal Phase 2 clinical trial for Dravet Syndrome (DS) and Phase 2 planning for Lennox-Gastaut Syndrome (LGS) is underway, with a projected launch date in 2023. 


Learn more about a Phase 2 Study for Dravet syndrome 


Learn more about our clinical program on

Powered by innovative science and steadfast commitment, Epygenix is working to quickly advance its multi-asset pipeline
to the clinic. We’re redefining how genetic epilepsy drugs
are discovered and developed.

bottom of page